SUPPORTING INFORMATION

In Silico, Experimental, Mechanistic Model for Extended-Release Felodipine Disposition Exhibiting Complex Absorption and a Highly Variable Food Interaction

Sean H. J. Kim, Andre J. Jackson, C. Anthony Hunt

Figure S1. Plasma concentration-time profile of an analog parameterized to Table 1’s default values.

Figure S2. Plasma concentration-time profile of the analog from Fig. S1 with $DtoGDelay = 5$ (default = 1) and $DtoGProb = 0.4$ (default = 0.8).
Figure S3. Plasma concentration-time profile of the analog from Fig. S1 with $DtoGFract$ set to 0.8 (default = 0.1).

Figure S4. Plasma concentration-time profile of the analog from Fig. S1 with $DiffGRatio = 0.5$ (default = 1) and $GAtoPFrac = 0.6$ (default = 0.1).
**Figure S5.** Plasma concentration-time profile of the analog from Fig. S1 with $\text{DiffGRatio} = 0.8$ (default = 1), $\text{GtoPFract} = 0.6$ (default = 0.1), and $\text{GBtoPFract} = 0.7$ (default = 0.1).

**Figure S6.** Plasma concentration-time profile of the analog from Fig. S1 with $\text{GtoCDelay} = 5$, $\text{GtoCFract} = 0.6$, $\text{GtoCPProb} = 0.7$, $\text{GCtoPDelay} = 15$, $\text{GCtoPFract} = 0.2$, and $\text{GCtoPPProb} = 0.2$, which specify drug movement to and from GI/tissue space $C$. 


Figure S7. Plasma concentration-time profile of the analog from Fig. S1 with $PtoEFract$ set to 0.6 (default = 0.1).

Figure S8. Plasma concentration-time profile of the analog from Fig. S1 with $PtoEDelay = 10$ (default = 0) and $PtoEFract = 0.6$ (default = 0.1).
**Figure S9.** Plasma concentration-time profile of the analog from Fig. S1 with $PtoEProb$ set to 0.2 (default = 0.8).

**Figure S10.** Plasma concentration-time profile of the analog from Fig. S1 with $InitDose$ increased to 50000 (default = 10000). No change in plasma profile is expected, which is measured in dose fraction.